Cabozantinib
CABOMETYX is a prescription medication containing cabozantinib, a kinase inhibitor that helps treat certain advanced cancers. It comes as oral tablets in strengths of 20 mg, 40 mg, and 60 mg, manufactured by Exelixis, Inc. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | CABOMETYX is a prescription medication containing cabozantinib, a kinase inhibitor that helps treat certain advanced cancers. It comes as oral tablets in strengths of 20 mg, 40 mg, and 60 mg, manufactured by Exelixis, Inc. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Cabozantinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Cabozantinib — ANDA 208692 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208692"
}
]
|
| identifier | ANDA208692 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"health-care",
"pharmaceuticals",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Cabozantinib |
